Tivic Health Signs Agreement with AmerisourceBergen for Retail Pharmacy Customers

August 2023

SAN FRANCISCO – August 28, 2023  Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that the Company has entered into a non-exclusive agreement with AmerisourceBergen, soon to be Cencora, to make Tivic’s products available on AmerisourceBergen’s third-party marketplace.

Tivic’s patented ClearUP bioelectronic sinus pain relief device will be offered on AmerisourceBergen Marketplace, the company’s new third-party marketplace, which launched on August 8. Marketplace seamlessly integrates into AmerisourceBergen’s existing ABC Order eCommerce platform, with the goal of creating a faster, more convenient shopping experience for its retail pharmacy customers to procure their storefronts. Tivic joins more than 50 verified suppliers on the Marketplace platform, which offers eligible pharmacies a variety of unique products in categories such as beauty, snacks, toys, personal care, and other everyday essentials all in one place.

“This is a strategic step in expanding our customer reach and product awareness with independent retail pharmacies,” said Ryan Sabia, COO of Tivic. “AmerisourceBergen is a well-respected commercial partner, and we see a compelling opportunity for our highly effective, clinically proven bioelectronic sinus device to thrive in its Marketplace for front-of-store products.”

About Tivic

Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic’s first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors.  For more information visit http://tivichealth.com @TivicHealth

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the company’s financial condition; the company’s ability to raise additional capital, if and when necessary; clinical trial results for the company’s product candidates; market and other conditions; supply chain constraints; macroeconomic factors, including inflation; and unexpected costs, charges or expenses that reduce Tivic’s capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic’s actual results to differ from those contained in the forward-looking statements, see Tivic’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023, under the heading “Risk Factors”; as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

Media Contact

Kayleigh Westerfield


Investor Contact

Hanover International, Inc.